ABIVAX company profile
Company profile
ABIVAX has 98 employees and is headquartered in Paris, France.
Obefazimod, the lead candidate in its pipeline, is the centre of ABIVAX's work and is being evaluated in moderately to severely active ulcerative colitis, with a separate study running in Crohn's disease. The Paris-based company, a clinical-stage biotech, develops therapies that draw on the body's own regulatory mechanisms to steady the immune response in people with chronic inflammatory diseases. Its programmes are aimed at patients suffering from chronic inflammatory conditions.
Revenue came to 4.6 million euros in the fiscal year ended 31 December 2025, down 63.2% on the prior year, while the net loss for that period reached 336.1 million euros. The company employs 98 people across its operations and has its headquarters in Paris, France, where it was incorporated in 2013.
Company facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- France
- Headquarters
- 7-11 Boulevard Haussmann, 75009, Paris
- Employees
- 98
- Chief executive
- Marc M. de Garidel
- Founded
- 2013
- Fiscal year
- January - December
- Listing
- ABVX · Euronext Paris
- Currency
- EUR
- ISIN
- FR0012333284
- Website
- abivax.com
ABIVAX and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| ABIVAXABVX | France | $6.06B | 98 | -6,270.4% | — |
| Bachem HoldingBANB | Switzerland | $6.84B | 2,725 | 21.8% | 38.7 |
| ALK-AbellóALK.B | Denmark | $7.79B | 2,795 | 26.6% | 38.0 |
| CamurusCAMX | Sweden | $4.32B | 323 | 37.4% | 58.7 |
| Financière de TubizeTUB | Belgium | $11.25B | 3 | 0.0% | 104.1 |
| Bavarian NordicBAVA | Denmark | $2.72B | 1,923 | 18.1% | 12.7 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
